Comparing two treatments for recurrent glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests if adding a wafer (Cerebraca) placed in the brain during surgery to standard chemotherapy (temozolomide) works better than chemotherapy alone for people whose glioblastoma has come back after first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have recurrent glioblastoma after first treatment (surgery, chemotherapy, and radiation)
- You have a brain tumor that can be seen on MRI and is at least 1 cm in size
- Your doctor believes the entire tumor can be safely removed with surgery
- You are able to care for yourself and do daily activities (Karnofsky score 70 or more)
- Your blood cell counts, kidney function, and liver function are within acceptable ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (D2C7-IT and 2141-V11) given directly into the brain after surgery for people with recurrent glioblastoma. The goal is to see if this treatment is safe and can help control the tumor.
This trial tests a combination of two drugs, triapine and temozolomide, for people whose glioblastoma has come back after initial treatment. The goal is to see if this combination can help control the tumor.
This trial tests a new cell therapy (P134 cells) for people whose glioblastoma has come back after standard treatments like radiation or chemotherapy. The therapy uses a patient's own immune cells (PBMCs) to target cancer cells that have specific markers (CD44 or CD133). It also requires a small procedure to place a reservoir under the scalp for drug delivery.
This trial studies whether combining three medicines can slow or shrink recurrent glioma (a type of brain tumor). It is for adults whose tumor has come back after standard treatment, with certain genetic tumor markers that may help guide whether you can join.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
Hear when a new Recurrent Glioblastoma, IDH-Wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.